Sarepta Forms Strategic Advisory Board
This article was originally published in Scrip
Sarepta Therapeutics Inc., a developer of RNA-targeted therapies, has formed a strategic and scientific advisory board (SSAB) with three key appointments: Dr Louis Kunkel, Dr Beverly Davidson, and Dr Jeffrey Chamberlain. The SSAB will work closely with Sarepta's management team to advance the company's platform technology in Duchene muscular dystrophy, identify multiple new applications for Sarepta's proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company's pipeline.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.